StoneX Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.23M | Buy |
32,707
+4,287
| +15% | +$922K | 0.33% | 48 |
|
|
2026
Q1 | $6.18M | Sell |
28,420
-18,263
| -39% | -$4.05M | 0.33% | 55 |
|
|
2025
Q4 | $10.7M | Buy |
46,683
+1,457
| +3% | +$332K | 0.46% | 33 |
|
|
2025
Q3 | $10.5M | Sell |
45,226
-1,932
| -4% | -$393K | 0.46% | 37 |
|
|
2025
Q2 | $8.75M | Sell |
47,158
-2,954
| -6% | -$549K | 0.43% | 41 |
|
|
2025
Q1 | $10.5M | Buy |
50,112
+1,414
| +3% | +$275K | 0.58% | 27 |
|
|
2024
Q4 | $8.65M | Buy |
+48,698
| New | +$8.95M | 0.48% | 30 |
|
|
2022
Q2 | – | Sell |
-20,335
| Closed | -$3.3M | – | 511 |
|
|
2022
Q1 | $3.3M | Sell |
20,335
-1,878
| -8% | -$273K | 0.31% | 58 |
|
|
2021
Q4 | $3.01M | Buy |
22,213
+3,894
| +21% | +$460K | 0.35% | 64 |
|
|
2021
Q3 | $1.98M | Sell |
18,319
-52
| -0.3% | -$5.94K | 0.28% | 71 |
|
|
2021
Q2 | $2.07M | Buy |
18,371
+1,422
| +8% | +$160K | 0.31% | 66 |
|
|
2021
Q1 | $1.83M | Buy |
16,949
+948
| +6% | +$101K | 0.33% | 47 |
|
|
2020
Q4 | $1.72M | Buy |
16,001
+741
| +5% | +$71.2K | 0.38% | 45 |
|
|
2020
Q3 | $1.34M | Buy |
15,260
+1,493
| +11% | +$141K | 0.43% | 47 |
|
|
2020
Q2 | $1.35M | Buy |
13,767
+1,343
| +11% | +$118K | 0.51% | 42 |
|
|
2020
Q1 | $947K | Buy |
12,424
+20
| +0.2% | +$1.7K | 0.5% | 50 |
|
|
2019
Q4 | $1.1M | Buy |
12,404
+1,781
| +17% | +$148K | 0.45% | 67 |
|
|
2019
Q3 | $804K | Buy |
10,623
+547
| +5% | +$37.5K | 0.5% | 60 |
|
|
2019
Q2 | $733K | Buy |
10,076
+1,740
| +21% | +$137K | 0.47% | 64 |
|
|
2019
Q1 | $672K | Buy |
8,336
+1,182
| +17% | +$96.7K | 0.51% | 64 |
|
|
2018
Q4 | $660K | Sell |
7,154
-153
| -2% | -$13.5K | 0.64% | 49 |
|
|
2018
Q3 | $691K | Buy |
7,307
+329
| +5% | +$31.2K | 0.51% | 63 |
|
|
2018
Q2 | $646K | Sell |
6,978
-189
| -3% | -$18.5K | 0.56% | 57 |
|
|
2018
Q1 | $678K | Sell |
7,167
-1,691
| -19% | -$186K | 0.65% | 40 |
|
|
2017
Q4 | $857K | Buy |
8,858
+493
| +6% | +$46.5K | 0.89% | 29 |
|
|
2017
Q3 | $743K | Sell |
8,365
-22,065
| -73% | -$1.68M | 0.93% | 29 |
|
|
2017
Q2 | $2.21M | Buy |
30,430
+19,878
| +188% | +$1.34M | 0.69% | 25 |
|
|
2017
Q1 | $661K | Sell |
10,552
-1
| -0% | -$63 | 1.48% | 27 |
|
|
2016
Q4 | $661K | Buy |
+10,553
| New | +$644K | 1.15% | 35 |
|
Other funds holding ABBV
StoneX Group's ABBV Position: Q2 2026 in Review
StoneX Group increased its AbbVie (ABBV) stake by 15% in Q2 2026, buying an estimated $922K and bringing the position to 32,707 shares worth $8.23M. The position accounts for 0.33% of the portfolio, ranked #48.
StoneX Group first reported a position in ABBV in Q4 2016 and has held it in 29 quarters since. The position peaked at $10.7M in Q4 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- StoneX Group held 32,707 shares of AbbVie worth $8.23M as of Q2 2026.
- StoneX Group bought 4,287 AbbVie shares in Q2 2026, an estimated $922K.
- AbbVie made up 0.33% of StoneX Group's portfolio in Q2 2026, its #48 holding.
- StoneX Group first reported a position in AbbVie in Q4 2016 and has held it in 29 quarters since.
- StoneX Group's AbbVie position peaked at $10.7M in Q4 2025.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.